RxDoctor Payments Data

Stacy Graham, MD

Interventional Cardiology · Columbia, SCNPI 1912093501

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $7,046 of the $8,281 with a category attached, or 85.1%. It is spread thinly across 34 manufacturers, the largest accounting for just 17.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,338 and has fallen 55.1% since, to $1,051 in 2025. That places this record below the midpoint for interventional cardiology clinicians in SC, where the typical reported total is $8,877.

$8,281in general payments, 2019–2025

Across 391 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$1K
  • Novartis$1K
  • Amgen$898
  • Pfizer$660
  • E.r. Squibb & Sons, L.L.C.$414
  • Boston Scientific$405
  • plus $3K from 28 others
$1,035in research payments, 2019–2025

Across 1 payment — averaging $1034.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$1K

What the payments were for

  • Travel & lodging$1,22115%
  • Food & beverage$7,04685%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,281 in reported general payments places this provider in the 45th percentile of 117 interventional cardiology providers in South Carolina.

See all interventional cardiology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$417,624
Medicare patients
2,024
Services billed
6,469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban522$501,604
XareltoRivaroxaban137$150,120
EntrestoSacubitril/Valsartan101$137,620
CamzyosMavacamten13$109,588
JardianceEmpagliflozin80$101,044
FarxigaDapagliflozin Propanediol74$64,200
Repatha SureclickEvolocumab84$63,721
Valsartan329$9,372
Metoprolol Succinate450$8,426
Rosuvastatin Calcium311$6,222
Atorvastatin Calcium427$5,164
Ezetimibe106$3,511
Diltiazem 24hr Er (Cd)Diltiazem Hcl84$2,844
Amlodipine Besylate441$2,800
Nifedipine ErNifedipine57$2,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$660$501,604522 claims
Johnson & JohnsonXarelto$354$150,120137 claims
NovartisEntresto$1,283$137,620101 claims
E.r. Squibb & Sons, L.L.C.Camzyos$414$109,58813 claims
Boehringer IngelheimJardiance$345$101,04480 claims
AstraZenecaFarxiga$385$64,20074 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 117 interventional cardiology providers in South Carolina.

Other interventional cardiology in Columbia

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →